In This Section      

Early Detection of Pancreatic Cancer Laboratory

Principal Investigator

Dr. Goggins started the Pancreatic Cancer Early Detection Research Laboratory in 1999. He is an Attending Physician and gastroenterologist at Johns Hopkins Hospital in the Department of Medicine, and Division of Gastroenterology/Hepatology and the Sol Goldman Professor of Pancreatic Cancer Research. He was promoted to Professor of Pathology, Medicine and Oncology in 2008. He has written or co-authored more than 300 peer-reviewed publications and is a highly cited investigator. He was a recipient of the 2012 AACR Team Science award. He is the PI of the NIH U01 grant that supports the multicenter Cancer of the Pancreas Screening-5, or “CAPS5” study. He is PI of an R01 from the NCI and an investigator for the Johns Hopkins SPORE in Gastrointestinal Cancer and co-PI of a Stand Up to Cancer/Lustgarten Foundation Pancreatic Cancer Interception grant. His research aims to improve the early detection of pancreatic cancer.

Selected Publications

  1. Yu J, Blackford A, Dal Molin M, et al. Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages. Gut. 2015;64:1783-89.
  2. Shindo K, Yu J, Suenaga M, et al. Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017;35(30):3382-90. Epub 2017/08/03.
  3. Suenaga M, Sadakari Y, Almario JA, et al. Using an endoscopic distal cap to collect pancreatic fluid from the ampulla. Gastrointestinal endoscopy. 2017. Epub 3/1/2017.
  4. Yarchoan M, Myzak MC, Johnson Iii BA, et al. Olaparib in combination with irinotecan, cisplatin, and mitomycin c in patients with advanced pancreatic cancer. Oncotarget. 2017. Epub 2017/04/30.
  5. Yu J, Sadakari Y, Shindo K, et al. Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms. Gut. 2017;66:1677-87.
  6. Canto MI, Almario JA, Schulick RD, et al. Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Gastroenterology. 2018;155(3):740-51.e2. Epub 2018/05/29.
  7. Suenaga M, Yu J, Shindo K, et al. Pancreatic Juice Mutation Concentrations Can Help Predict the Grade of Dysplasia in Patients Undergoing Pancreatic Surveillance. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018;24(12):2963-74. Epub 2018/01/06.
  8. Tamura K, Yu J, Hata T, et al. Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America. 2018;115(18):4767-72. Epub 2018/04/20.
  9. Abe T, Blackford AL, Tamura K, et al. Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019;37(13):1070-80. Epub 2019/03/19.
  10. Engle DD, Tiriac H, Rivera KD, et al. The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. Science (New York, NY). 2019;364(6446):1156-62. Epub 2019/06/22.
  11. Goggins M, Overbeek KA, Brand RE, et al. Management of patients with increased risk for familial pancreatic cancer: updated guidelines from the international Cancer of the Pancreas Screening (CAPS) consortium Gut. 2019;in press.
  12. Wood LD, Yurgelun MB, Goggins MG. Genetics of Familial and Sporadic Pancreatic Cancer. Gastroenterology. 2019. Epub 2019/01/21.